Kenvue Inc. (NYSE:KVUE - Get Free Report) has been assigned a consensus rating of "Hold" from the fifteen research firms that are covering the firm, MarketBeat.com reports. Twelve analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $19.2727.
KVUE has been the subject of several research reports. UBS Group lowered their price objective on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Tuesday, August 11th. Barclays raised their target price on Kenvue from $18.00 to $19.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 21st. Weiss Ratings raised Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, June 15th. Zacks Research downgraded Kenvue from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen lowered Kenvue from a "buy" rating to a "hold" rating in a report on Saturday, August 8th.
View Our Latest Report on KVUE
Hedge Funds Weigh In On Kenvue
Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Kenvue during the 2nd quarter worth about $2,882,279,000. California State Teachers Retirement System raised its position in shares of Kenvue by 1,695.1% during the 2nd quarter. California State Teachers Retirement System now owns 56,438,843 shares of the company's stock worth $1,078,546,000 after acquiring an additional 53,294,807 shares in the last quarter. Pentwater Capital Management LP acquired a new stake in shares of Kenvue during the 2nd quarter worth about $977,094,000. Norges Bank purchased a new stake in Kenvue during the fourth quarter worth approximately $756,862,000. Finally, Independent Franchise Partners LLP boosted its holdings in Kenvue by 56.3% in the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company's stock valued at $830,527,000 after purchasing an additional 17,343,785 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.
Kenvue Trading Up 0.1%
Shares of NYSE:KVUE opened at $17.77 on Friday. Kenvue has a 12-month low of $14.02 and a 12-month high of $20.13. The business's fifty day simple moving average is $19.09 and its 200-day simple moving average is $18.24. The company has a market capitalization of $34.14 billion, a PE ratio of 20.43, a P/E/G ratio of 1.58 and a beta of 0.46. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion during the quarter, compared to analysts' expectations of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm's quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.29 EPS. As a group, equities research analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, October 2nd. Shareholders of record on Monday, September 21st will be given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 4.7%. The ex-dividend date of this dividend is Monday, September 21st. Kenvue's dividend payout ratio (DPR) is currently 96.55%.
Kenvue Company Profile
(
Get Free Report)
Kenvue Inc is a global consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, essential health products, and baby and family care.
The company's brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; Listerine in oral care; and Johnson's and Band-Aid in baby care and essential health.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.